XML 215 R7.htm IDEA: XBRL DOCUMENT v3.25.0.1
CONSOLIDATED STATEMENTS OF EQUITY - USD ($)
$ in Thousands
Total
Total Lisata Therapeutics, Inc. Stockholders' Equity
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive Loss
Accumulated Deficit
Treasury Stock
Non- Controlling Interest in Subsidiary
Beginning Balance (in shares) at Dec. 31, 2022     7,867,000          
Beginning Balance at Dec. 31, 2022 $ 66,324 $ 66,578 $ 8 $ 574,548 $ (29) $ (507,241) $ (708) $ (254)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net loss (20,840) (20,840)       (20,840)    
Share-based compensation (in shares)     114,000          
Share-based compensation 1,947 1,947   1,947        
Net proceeds from issuance of common stock (in shares)     87,000          
Net proceeds from issuance of common stock 321 321   321        
Proceeds from option exercises (in shares)     83,000          
Proceeds from option exercises 155 155   155        
Unrealized gain on marketable securities 12 12     12      
Foreign currency translation adjustment $ (25) (25)     (25)      
Ending Balance (in shares) at Dec. 31, 2023 8,149,897   8,151,000          
Ending Balance at Dec. 31, 2023 $ 47,894 48,148 $ 8 576,971 (42) (528,081) (708) (254)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net loss (19,985) (19,985)       (19,985)    
Share-based compensation (in shares)     218,000          
Share-based compensation 1,379 1,379   1,379        
Net proceeds from issuance of common stock (in shares)     28,000          
Net proceeds from issuance of common stock $ 68 68   68        
Proceeds from option exercises (in shares) 13,345   13,000          
Unrealized gain on marketable securities $ 1 1     1      
Foreign currency translation adjustment $ (40) (40)     (40)      
Ending Balance (in shares) at Dec. 31, 2024 8,408,844   8,410,000          
Ending Balance at Dec. 31, 2024 $ 29,317 $ 29,571 $ 8 $ 578,418 $ (81) $ (548,066) $ (708) $ (254)